General Information

We are a preclinical biopharmaceutical company developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT, and expect to generate clinical safety and efficacy data in 2018. Our i-ERT approach is enabled by our proprietary Hybrid mRNA Technology platform, which allows synthesis of the missing enzyme inside the cell. Our initial product portfolio targets the three urea cycle disorders OTCD, ASL deficiency and ASS1 deficiency.

Employees: 16
Founded: 2006
Contact Information
Address 410 W. Harrison Street, Suite 300, Seattle, WA 98119, US
Phone Number (206) 805-6300
Web Address
View Prospectus: PhaseRx
Financial Information
Market Cap $57.9mil
Revenues $0 mil (last 12 months)
Net Income $-8.2 mil (last 12 months)
IPO Profile
Symbol PZRX
Exchange NASDAQ
Shares (millions): 3.7
Price range $5.00 - $5.00
Est. $ Volume $18.5 mil
Manager / Joint Managers Laidlaw & Company (UK) Ltd./ Roth Capital Partners
CO-Managers -
Expected To Trade: 5/18/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change